Imugene (IMU) Q3 2026 TU earnings summary

Executive summary

• Positive Phase 1b clinical trial results for azer-cel in CAR T-naive cohorts: 100% ORR in CLL/SLL and 80% ORR in MZL, with protocol expansion to include BTKi combination and MCL indication.

• Strategic focus on lead asset azer-cel, with discontinuation of CF33 (VAXINIA) program to prioritize high-value opportunities.

• Azer-cel data selected for oral presentation at ASCO 2026, highlighting clinical merit and visibility.

Financial highlights

• Cash and cash equivalents at 31 March 2026: $5.963 million, following the first tranche of a $16 million capital raise.

• Net cash used in operating activities for the quarter: $9.673 million; R&D expenses comprised 76% of total operating costs.

• R&D tax refund of A$2,738,618 received for FY2025.

• Additional $5.62 million and $4.0 million from SPP received post-quarter end.

Outlook and guidance

• Key near-term catalysts include ASCO abstract publication (21 May 2026), oral presentation (29 May–2 June 2026), and updated naive cohort data.

• Enrollment in BTKi combination cohort and further data readouts expected.